Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment

Priscyla Zenteno-Castillo, Daniela Beatriz Muñoz-López, Benjamín Merino-Reyes, Ángel Vega-Sánchez, Monica Preciado-Puga, Ana Lilia González-Yebra, Carlos Kornhauser, Priscyla Zenteno-Castillo, Daniela Beatriz Muñoz-López, Benjamín Merino-Reyes, Ángel Vega-Sánchez, Monica Preciado-Puga, Ana Lilia González-Yebra, Carlos Kornhauser

Abstract

Objective: To determine the prevalence of Diabetic Nephropathy (DN) in patients with type 2 Diabetes Mellitus (T2DM) with over 5 years of evolution in rural communities of Guanajuato, Mexico, and evaluate the effects of an ARB treatment over 6 months in patients with DN.

Materials and methods: Patients of both sexes, 38-86 years, T2DM over 5 years of evolution and diagnosed with arterial hypertension (HT) after T2DM incidence. Monthly determination of microalbuminuria (MA), lipids, glucose, serum creatinine, and glycated hemoglobin (HbA1c). Estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD) formula. A dose of 80 mg of Telmisartan was administered daily over 6 months.

Results: The total adult population of two rural communities (3609 subjects) was studied, 335 subjects had T2DM, among them 80 (with a prevalence of 24%) had DN and HT. Sixty-seven patients received Telmisartan, and showed significant improvement in all parameters studied.

Conclusions: A higher prevalence of DN than that reported in the Mexican National Health Survey (ENSANUT) was found. Further research is required in a larger population sample in order to confirm the results of Telmisartan treatment.

Keywords: Biomarkers; Diabetic nephropathy; Prevalence; Telmisartan; Type 2 diabetes mellitus.

Figures

Figure 1
Figure 1
Comparison of the number of stratification cases, according to the K/DOQI at the beginning and the end of the study.

References

    1. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2006. <; >. [Online] accessed 28.09.13.
    1. Ortuño J. Diabetes mellitus y Nefropatía diabética, ¿Cuál es la magnitud del problema? Nefrología. 2001;21(3):4–11.
    1. Ono T., Shikata K., Obika M., Miyatake N., Kodera R., Hirota D. Factors associated with remission and/or regression of microalbuminuria in type 2 diabetes mellitus. Acta Med Okayama. 2014;68(4):235–241.
    1. Olmos P., Araya-Del-Pino A., Gonzalez C., Laso P., Irribarra V., Rubio L. Fisiopatología de la retinopatía y nefropatía diabéticas. Rev Med Chile. 2009;137(10):1375–1384.
    1. Perkins B.A., Ficociello L.H., Silva K.H., Finkelstein D.M., Warram J.H., Krolewski A.S. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–2293.
    1. Ritz E., Zheng X. Diabetic nephropathy – epidemiology in Asia and the current state of treatment. Indian J Nephrol. 2011;21(2):75–84.
    1. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med. 2008;233(1):4–11.
    1. Valmadrid C.T., Klein R., Moss S.E., Klein B.E.K. The risk of mortality cardiovascular disease associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093–1100.
    1. Ali A., Taj A., Amin M.J., Iqbal F., Iqbal Z. Correlation between microalbuminuria and hypertension in type 2 diabetic patients. Pak J Med Sci. 2014;30(3):511–514.
    1. Collins A.J., Foley R.N., Chavers B., Gilbertson D., Herzog C., Johansen K. United States renal data system 2011 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1:A7):e1–420.
    1. Makino H., Haneda M., Babazono T., Moriya T., Ito S., Iwamoto Y. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–1578.
    1. Saito Y., Hongwei W., Ueno H., Mizuta M., Nakazato M. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD (P) H oxidase activity in pancreatic B-cells. Diabetes Metab. 2009;35(5):392–397.
    1. Durán-Salgado M.B., Rubio-Guerra A.F. Diabetic nephropathy and inflammation. World J Diabetes. 2014;5(3):393–398.
    1. Gnudi L., Goldsmith D. Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. Med Rep. 2010;18(2):1–4.
    1. Brenner B.M., Copper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.-H. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. n Engl J Med. 2001;1345(12):861–869.
    1. Diaz Flores M., Baiza Gutman L.A., Ibáñez Hernández M.A., Pascoe Lira D., Guzmán Greenfel A.M., Kumate Rodríguez J. Aspectos moleculares de daño tisular inducido por la hiperglucemia crónica. Gac Med Mex. 2004;140(4):437–448.
    1. Meeme A., Kasozi H. Effect of glycemic monitoring on glomerular filtration rate in Diabetes Mellitus patients. Afr Health Sci. 2009;9(Suppl. 1):S23–6.
    1. Ley General de Salud en Materia de Investigación accessed 04.02.14.
    1. Kumar A., Kapoor S., Gupta R.C. Comparison of urinary protein: creatinine index and dipsticks for detection of microproteinuria in diabetes mellitus patients. J Clin Res. 2013;7(4):622–626.
    1. Michels W.M., Grootendorst D.C., Verduijn M., Elliott E.G., Dekker F.W., Krediet R.T. Performance of the cockcroft-gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003–1009.
    1. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–886.
    1. Plantinga L.C., Crews D.C., Coresh J., Miller E.R., III, Saran R., Yee J. CDC surveillance team CKD: prevalence of chronic kidney disease in US Adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–682.
    1. Castañeda Sánchez O., Lopez del Castillo Sánchez D., Araujo Lopez A. Apego farmacológico en pacientes con hipertensión arterial de una Unidad de Medicina Familiar de Ciudad Obregón, Sonora (México) Arch Med Fam. 2008;10(1):3–9.
    1. Instituto Nacional de Estadística y Geografía, Cuéntame de México 2010. [Online]
    1. Watanabe M., Inukai K., Sumita T., Ikebukuro K., Ito D., Kurihara S. Effects of telmisartan on insulin resistance in type 2 diabetic patients Japanese. Inter Med. 2010;43(17):1843–1847.
    1. Li L., Luo Z., Yu H., Feng X., Wang P., Chen J. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation. Diabetes. 2013;62(3):762–774.
    1. Chai W., Wang W., Liu J., Barrett E.J., Carey R.M., Cao W. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension. 2010;55(2):523–530.
    1. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes. 2005;54(12):3442–3452.
    1. Leto D., Saltiel A.R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol. 2012;13(6):383–396.
    1. Brunham L.R., Kruit J.K., Pape T.D., Timmins J.M., Reuwe A.Q., Vasanji Z. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13(3):340–347.
    1. Clemenz M., Frost N., Schupp M., Caron S., Foryst Ludwig A., Böhm C. Liver-specific peroxisome proliferator-activated receptor α target gene regulation by the angiotensin type 1 receptor blocker Telmisartan. Diabetes. 2008;57(5):1405–1413.
    1. Kramer D.K., Al Khalili L., Guigas B., Leng Y., Garcia Roves P.M., Krook A. Role of AMP kinase and PPAR delta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem. 2007;282(27):19313–19320.
    1. Schuler M., Ali F., Chambon C., Duteil D., Bornet J.M., Tardivel A. PGC1 alpha expression is controlled in skeletal muscles by PPAR beta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006;4(5):407–414.
    1. Gan Z., Burkart Hartman E.M., Han D.H., Finck B., Leone T.C., Smith E.Y. The nuclear PPAR/δ programs muscle glucose metabolism receptor in cooperation with AMPK and MEF2. Genes Dev. 2011;25(24):2619–2630.
    1. Luquet S., Lopez Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M. Peroxisome proliferator-activated receptor controls muscle development and oxidative capability delta. FASEB J. 2003;17(15):2299–2301.
    1. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M. PPAR delta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA. 2006;103(9):3444–3449.
    1. Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga Ocampo C.R. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2004;2(10):E294.
    1. Duran Varela B.R., Rivera Chavira B., Franco Gallegos E. Apego al tratamiento farmacológico en pacientes con diagnóstico de diabetes mellitus tipo 2. Salud Publica Mex. 2001;43(3):223–236.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa